Alzheimer's Disease Pathway — Interactive Enrichment Demo

Alzheimer's Disease Pathway

Interactive enrichment-driven map — APP processing, Aβ aggregation, tau hyperphosphorylation

Build your antibody bundle ↓
Interactive Pathway Map — click a gene
Alzheimer's Disease Pathway interactive map

Biomarker Roles & PicoBand® Antibody Bundle

Target SKU Reactivity Application Size CheckPlease select at least 4 targets.
SNCA A00215-3 Human, Mouse, Rat ELISA, Flow Cytometry, IF, IHC, ICC, WB 100 μg/vial
APP (Senile Plaque) A00081-3 Human IHC, WB 100 μg/vial
IL1B (IL-1) A00101 Human, Mouse, Rat WB 100 μg/vial
TNF A00002-2 Mouse WB 100 μg/vial
CACNA1C (VDCC) No PicoBand® antibody for this target — null
GRIN2B (NMDAR) PB9373 Mouse, Rat WB 100 μg/vial
GRM1 (GPCR) A03049-4 Human, Mouse, Rat WB, IHC, Flow Cytometry, ELISA 100 μg/vial
FAS (Fas/TNFR) A00055 Mouse, Rat ELISA, Flow Cytometry, WB 100 μg/vial
LRP1 (LRP) No PicoBand® antibody for this target — null
LPL No PicoBand® antibody for this target — null
APOE (ApoE) A00015-5 Human ELISA, Flow Cytometry, IF, IHC, ICC, WB 100 µg/vial
MME (NEP) PB9058 Human, Rat Flow Cytometry, IHC, WB 100 μg/vial
IDE A01358-2 Human, Mouse, Rat ELISA, Flow Cytometry, IHC, ICC, WB 100 μg/vial
ADAM10 (α-secretase ADAM) A00566-1 Human, Mouse, Rat WB, ELISA 100 μg/vial
BACE1 (β-secretase BACE) A00322-3 Human, Mouse, Rat WB, ELISA 100 μg/vial
GAPDH A00227-1 Chicken, Human, Monkey, Mouse, Rat, Zebrafish IF, IHC, ICC, WB, Flow Cytometry 100 μg/vial
APBB1 (Fe65) RP1059 Human, Mouse WB 100 μg/vial
NAE1 (APP-BP1) PB9339 Human, Mouse, Rat WB 100 μg/vial
PSENEN (PEN2) No PicoBand® antibody for this target — null
PSEN1 (PSEN) A00138-3 Human, Mouse, Rat ELISA, Flow Cytometry, IF, ICC, WB 100 μg/vial
NCSTN A03144-1 Human, Mouse, Rat WB, ICC, IF, ELISA 100 μg/vial
APH1A (APH1) A04859-1 Human, Mouse, Rat Flow Cytometry, IHC, WB 100 μg/vial
CASP3 (CASP3 (apop)) A00334-2 Human WB, ICC, IF, Flow Cytometry 100 μg/vial
CASP7 A01044-2 Human, Rat ELISA, Flow Cytometry, IF, IHC, ICC, WB 100 μg/vial
CAPN1 (CALPAIN) PA1364 Human, Mouse, Rat IF, IHC, IHC-F, ICC, WB 100 μg/vial
CDK5R1 (p25) No PicoBand® antibody for this target — null
CDK5 A00511-1 Human, Mouse, Rat ELISA, IHC, WB 100 μg/vial
MAPT (Tau) A00097-3 Human, Mouse, Rat ELISA, IF, IHC, ICC, WB 100 μg/vial
GSK3B A00791-3 Human, Mouse, Rat ELISA, IF, IHC, ICC, WB 100 μg/vial
NOS1 (NOS) A01070 Human, Mouse, Rat WB 100 μg/vial
NOS2 (ONOO-) A00368 Human IHC, WB 100 μg/vial
GNAQ (Gq) PB9707 Human, Mouse, Rat Flow Cytometry, IF, IHC, ICC, WB 100 μg/vial
PLCB1 (PLC) A02817-1 Human, Mouse, Rat WB, ELISA 100 µg/vial
ITPR1 (IP3) PB9225 Human, Mouse, Rat Flow Cytometry, IF, IHC, ICC, WB 100 μg/vial
FADD PA1464 Human, Mouse, Rat WB 100 μg/vial
CASP8 A00042 Human, Mouse, Rat Flow Cytometry, IHC, IHC-F, ICC, WB 100 μg/vial
BID A00730 Mouse, Rat Flow Cytometry, IHC, WB 100 μg/vial
CALM1 (CaM) No PicoBand® antibody for this target — null
MAPK1 (ERK1/2) PA1310 Human, Mouse, Rat WB 100 μg/vial
CHP1 (CHP) A04737-3 Human, Mouse, Rat WB, ICC, IF, Flow Cytometry 100 μg/vial
BAD (Bad) A03520-3 Human, Mouse WB, Flow Cytometry 100 μg/vial
APAF1 (Apaf1) A00889-2 Human WB, Flow Cytometry, ELISA 100 μg/vial
CYCS (CytC) A03529 Human, Mouse, Rat IHC, WB 100 μg/vial
CASP9 A00080-5 Human WB, IHC, ICC, IF, Flow Cytometry, ELISA 100 μg/vial
RYR2 (RyR) A00155-2 Human WB, IHC, ELISA 100 μg/vial
EIF2AK3 (PERK) A01992-2 Human ELISA, IHC, WB 100 μg/vial
ERN1 (IRE1a) A00683-1 Human, Mouse, Rat ELISA, Flow Cytometry, IF, ICC, WB 100 μg/vial
ATF6 A00655 Human, Mouse, Rat IHC, WB 100 μg/vial
CASP4 (CASP12) A02941-1 Human ELISA, Flow Cytometry, IF, IHC, ICC, WB 100 μg/vial
NDUFS1 (Cx I) A04920-1 Human, Mouse, Rat ELISA, Flow Cytometry, IHC, WB 100 μg/vial
SDHA (Cx II) A01753 Human, Mouse, Rat Flow Cytometry, IF, ICC, WB 100 μg/vial
UQCRC1 (Cx III) No PicoBand® antibody for this target — null
MT-CO1 (Cx IV) PA1317 Human WB 100 μg/vial
NDUFA9 (Cx V) A07420-3 Human, Mouse, Rat ELISA, Flow Cytometry, IF, IHC, ICC, WB 100 µg/vial
HSD17B10 (ABAD) PB9336 Human Flow Cytometry, IF, IHC, ICC, WB 100 μg/vial
ATP2A2 (SERCA) No PicoBand® antibody for this target — null
✓In stock items Ship Next Business Day. For Europe, ships in: 2-3 weeks.
Saved $0
Price: $0/0*0

What Is the Alzheimer's Disease Pathway?

The molecular cascade behind progressive neurodegeneration

The Alzheimer's disease pathway is the network of molecular events that drives the irreversible decline in cognitive and behavioral ability that defines Alzheimer's disease (AD). It is built on two convergent protein-misfolding axes: the amyloid secretase pathway, which generates and aggregates β-amyloid (Aβ) peptides into extracellular neuritic plaques, and the tau pathway, in which hyperphosphorylated tau detaches from microtubules and assembles into intraneuronal neurofibrillary tangles (NFTs).

These two lesions do not act in isolation. Aβ oligomers trigger inflammatory cascades, dysregulated calcium handling, oxidative stress, and neuronal apoptosis, and they promote tau phosphorylation. Upstream kinases — most notably GSK3β — and the Wnt signaling axis sit above both lesions, linking impaired Aβ clearance, tau hyperphosphorylation, reduced neurogenesis, and amplified apoptosis into one self-reinforcing program.

Understanding the Alzheimer's disease signaling pathway is foundational for research in neurodegeneration, biomarker discovery, and the development of disease-modifying therapeutics that target the underlying biology rather than only the cholinergic symptoms.

Schematic of the Alzheimer's disease pathway: amyloid plaque formation from APP processing and neurofibrillary tangle formation from hyperphosphorylated tau converging on synaptic loss and neuronal death
Pathway overview: APP processing and Aβ aggregation on one axis, tau hyperphosphorylation and neurofibrillary-tangle formation on the other, converging on synaptic loss and neuronal death.

Key Takeaways at a Glance

What every researcher should know before designing an Alzheimer's-pathway experiment.

Aβ42 Oligomers Are the Toxic Species

Soluble Aβ42 oligomers, not mature plaques, drive synaptotoxicity — triggering inflammation, calcium dysregulation, oxidative stress, and tau phosphorylation. The β-/γ-secretase processing balance is the molecular control point of the amyloid secretase pathway.

Tau Phosphorylation State Is Decisive

Tau has ~79 serine/threonine phosphorylation sites. The phosphorylation/dephosphorylation equilibrium — governed by GSK3β, CDK5, MAPK and phosphatases PP1/PP2A/PP5 — decides whether microtubules stay stable or collapse into neurofibrillary tangles.

GSK3β Is the Convergence Node

Hyperactive GSK3β simultaneously hyperphosphorylates tau, promotes amyloidogenic APP cleavage, suppresses neurogenesis, and amplifies apoptosis. Wnt signaling normally restrains it — Wnt loss in AD removes that brake.

The Tau Protein Pathway in Alzheimer's Disease

From microtubule stabilization to neurofibrillary tangles

Diagram of the tau pathway: normal tau stabilizing axonal microtubules, then hyperphosphorylation by GSK3-beta and CDK5 with reduced PP2A causing tau to detach and microtubules to collapse, then aggregation into paired helical filaments and a neurofibrillary tangle
Tau pathway: tau normally stabilizes axonal microtubules; hyperphosphorylation (GSK3β, CDK5; reduced PP2A) detaches tau and collapses microtubules; released tau aggregates into paired helical filaments and neurofibrillary tangles.

Tau Metabolism & Function

Tau is a microtubule-associated protein concentrated in the central and peripheral nervous system and a key part of the neuronal cytoskeleton. By interacting with α- and β-tubulin it stabilizes microtubules, which are essential for neuronal structure, synaptic plasticity, and axonal transport.

  • Six tau isoforms occur in humans, differing at the N-terminus and in the number of tubulin-binding repeat domains (three or four)
  • Tau carries roughly 79 serine/threonine phosphorylation sites
  • The phosphorylation/dephosphorylation balance controls how tau binds tubulin and how strongly it stabilizes microtubules
  • Embryonic neuronal tau is highly phosphorylated for neuroplasticity; mature CNS requires dephosphorylated tau for cytoskeletal homeostasis

Abnormal hyperphosphorylation impairs tubulin binding, damages microtubule architecture, disrupts axonal transport, and ultimately causes cytoskeletal breakdown and neuronal death.

Kinases & Phosphatases Controlling Tau

A network of kinases and phosphatases sets the tau phosphorylation state:

  • GSK3β (glycogen synthase kinase 3β) is the central tau kinase in neurons
  • Proline-directed kinases — CDK5, CDC2, and the MAPK family — phosphorylate tau at Ser/Thr-Pro motifs and are found in AD cortical tissue
  • Non-proline-directed kinases — PKC, casein kinases I and II, CaMKII, and PKA — modulate the activity of the above and are present in NFTs
  • Phosphatases PP1, PP2A, and PP5 show reduced activity in AD cerebral tissue, shifting the balance toward hyperphosphorylation

Loss of phosphatase activity combined with kinase hyperactivity produces the pathologically hyperphosphorylated tau that seeds tangle formation.

Tau & Neurofibrillary Tangles

Neurofibrillary tangles are intraneuronal lesions composed mainly of paired helical filaments (PHFs) of hyperphosphorylated tau:

  • 25+ abnormal phosphorylation sites are described in AD tau
  • Hyperphosphorylation near the tubulin-binding domain disaggregates the tau–tubulin complex
  • Released tau rearranges into PHFs that assemble into NFTs
  • NFT spread through the brain correlates with the clinical progression of dementia

Intraneuronal hyperphosphorylated tau is detectable in mild dementia even without β-amyloid pathology, suggesting tau dysregulation can be an early initiating event.

GSK3β, Wnt Signaling & AD

GSK3β is a hub linking the tau and amyloid axes:

  • Wnt signaling normally inactivates GSK3β, restraining tau phosphorylation at GSK-dependent epitopes
  • In AD, GSK3β is hyperactive, driving tau hyperphosphorylation
  • GSK3β also controls APP metabolism and favors amyloidogenic cleavage (excess Aβ)
  • GSK3β hyperactivity decreases neurogenesis and amplifies apoptosis

Because GSK3β sits upstream of both lesions, it is one of the most studied convergence-node drug targets in the Alzheimer's disease pathway.

Pathway Crosstalk: Integrating Alzheimer's Signaling Into Your Maps

How the amyloid and tau axes converge with inflammation, calcium, and apoptosis

The Alzheimer's disease pathway is not a single linear chain. The amyloid and tau axes are coupled to each other and to the major stress- and death-signaling systems of the neuron. Mapping these connections prevents misinterpretation of experimental results and reveals where intervention is most tractable.

Amyloid → Tau Crosstalk

Aβ oligomers activate neuronal kinases — prominently GSK3β and CDK5 — that hyperphosphorylate tau. This is the molecular bridge between the two hallmark lesions: amyloid pathology accelerates tau pathology, while tau is required for Aβ-induced neurotoxicity. Targeting only one axis often leaves the other to drive progression.

Neuroinflammation Crosstalk

Aβ deposits activate microglia and astrocytes, releasing IL-1β, TNF-α, and other mediators. This neuroinflammatory response further impairs Aβ clearance and amplifies neuronal injury, creating a feed-forward loop in which inflammation both responds to and aggravates the amyloid burden.

Calcium & Oxidative-Stress Crosstalk

Aβ oligomers form membrane pores and dysregulate intracellular calcium, while mitochondrial dysfunction raises reactive oxygen species. Calcium dyshomeostasis and oxidative stress reinforce each other and feed back onto kinase activity, further driving tau phosphorylation and synaptic failure.

Wnt / GSK3β Crosstalk

Wnt signaling normally inactivates GSK3β. Loss of Wnt tone in AD releases GSK3β, which simultaneously hyperphosphorylates tau, biases APP toward amyloidogenic cleavage, suppresses neurogenesis, and promotes apoptosis — making the Wnt/GSK3β node a single lever that moves both lesions at once.

Pathway crosstalk diagram: GSK3-beta as a central hub with bidirectional connections to the amyloid axis (APP/BACE1/Abeta), the tau axis (hyperphosphorylated tau to NFT), neuroinflammation (microglia, IL-1, TNF), calcium and oxidative stress (mitochondria), and Wnt signaling
Pathway crosstalk: GSK3β as a central hub with annotated bidirectional connections to the amyloid axis (APP/BACE1/Aβ), the tau axis (hyperphosphorylated tau → NFT), neuroinflammation (microglia, IL-1β, TNF-α), calcium/oxidative stress (mitochondria), and Wnt signaling.

Cell-Type-Specific Roles in the Alzheimer's Pathway

The same amyloid and tau machinery produces different outcomes depending on which CNS cell type is involved. These are the most experimentally relevant contexts.

  • Neurons: Lesion Formation and Death

    Neurons are where both hallmark lesions originate. APP processing generates Aβ at the membrane; intraneuronal hyperphosphorylated tau disaggregates from microtubules and forms PHFs/NFTs. The combination disrupts axonal transport and synaptic metabolism, causing cytoskeletal breakdown and neuronal death — the substrate of cognitive decline.

  • Microglia: Neuroinflammatory Response

    Microglia sense Aβ deposits and mount an inflammatory response, releasing IL-1β, TNF-α, and other mediators. While intended to clear amyloid, chronic microglial activation impairs Aβ clearance and amplifies neuronal injury, making microglia a central node in the feed-forward inflammatory loop of the Alzheimer's disease pathway.

  • Astrocytes: Clearance and Support

    Astrocytes contribute to Aβ uptake and degradation and to ApoE-mediated lipid and amyloid handling. Reactive astrogliosis is a consistent feature of AD tissue; impaired astrocytic clearance tips the balance toward net Aβ accumulation and contributes to synaptic dysfunction.

  • Cholinergic Neurons: Neurotransmitter Loss

    Degeneration of cholinergic neurons reduces acetylcholine, the basis of the cholinergic symptom axis. Acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine, tacrine) raise synaptic acetylcholine to partially offset this loss, but treat symptoms rather than the underlying amyloid/tau biology.

  • Blood-Brain Barrier: Aβ Efflux

    Clearance of Aβ from the brain depends in part on transport across the blood-brain barrier together with ApoE and the insulin-degrading enzyme (IDE). Impaired efflux and reduced enzymatic degradation in disease shift the Aβ production/clearance balance toward accumulation even when production is near-normal.

The Amyloid Secretase Pathway

Amyloidogenic vs. non-amyloidogenic processing of APP

Amyloid precursor protein (APP) is an integral polytopic protein highly expressed in the central nervous system and present in peripheral epithelium and blood cells. APP is processed by two competing routes, and the balance between them determines whether toxic Aβ accumulates.

Route Initiating Enzyme Fragments Produced Outcome
Non-amyloidogenic α-secretase (within the Aβ domain) sAPPα (soluble N-terminal) + C83 C83 cleaved by γ-secretase to the short P3 fragment; no intact Aβ — neuroprotective default route
Amyloidogenic β-secretase (BACE1) sAPPβ (shorter N-terminal) + C99 C99 cleaved by γ-secretase to full-length Aβ (Aβ40 / Aβ42)
Aggregation Concentration-driven (Aβ42 prone) Monomers → dimers → oligomers → protofibrils → fibrils Mature into diffuse, then neuritic, then senile amyloid plaques

In the non-amyloidogenic pathway, α-secretase cleaves APP within the Aβ sequence, releasing sAPPα and the membrane-bound C83 fragment, which γ-secretase further trims to the innocuous P3 peptide. No intact Aβ is generated. Under physiological conditions this is the preferred route, and a balance is maintained between the small amount of Aβ produced and its clearance.

In the amyloidogenic pathway, β-secretase (BACE1) cleaves APP to sAPPβ and C99; γ-secretase then liberates the full-length Aβ peptide. Aβ40 and Aβ42 dominate in the brain, with Aβ42 the more aggregation-prone and neurotoxic species and the central driver of AD pathogenesis. Secreted Aβ monomers progressively assemble into dimers, oligomers, protofibrils, and fibrils that deposit and mature into amyloid plaques.

The soluble Aβ oligomers — not the mature plaques — are regarded as the most lethal species. They interact with neurons and glia to trigger inflammatory cascades, dysregulated calcium metabolism, oxidative stress, neuronal apoptosis, and tau phosphorylation. Clearance normally depends on Apolipoprotein E (ApoE) and the insulin-degrading enzyme (IDE); in disease, a metabolic shift toward amyloidogenic cleavage plus reduced clearance drives net Aβ accumulation.

Two-panel APP-processing diagram: non-amyloidogenic route (alpha- then gamma-secretase, sAPPalpha + P3, no Abeta) and amyloidogenic route (beta-secretase/BACE1 then gamma-secretase, sAPPbeta + C99 + Abeta) ending in the Abeta aggregation cascade into amyloid plaques
Two-panel APP-processing diagram: non-amyloidogenic route (α- then γ-secretase, sAPPα + P3, no Aβ) on top; amyloidogenic route (β-secretase/BACE1 then γ-secretase, sAPPβ + C99 + Aβ) below, ending in the Aβ aggregation cascade into plaques.
Reference: KEGG hsa05010 — Alzheimer's disease pathway

Alzheimer's Disease Stages and Pathological Progression

How lesions spread anatomically as the disease advances

AD pathology begins years before symptoms and spreads through the brain in a stereotyped anatomical sequence, which is why pathway readouts are interpreted differently depending on disease stage.

Clinical-pathological stages

  • Preclinical AD: the first pathological changes strike the entorhinal cortex and then the hippocampus; symptoms limited to mild amnesia that does not affect daily activity
  • Mild AD: pathology extends into the cerebral cortex; visible cognitive signs — amnesia, impaired problem-solving, personality and mood changes, disorientation
  • Moderate AD: pathology reaches regions controlling speech, reasoning, and sensory processing; behavioral changes, withdrawal, and failure to recognize family appear
  • Chronic (severe) AD: breakdown spreads across the cortex; loss of control over daily activity plus systemic signs — dyspraxia, olfactory dysfunction, sleep disturbance, dystonia, akathisia, parkinsonian features

Genetic and risk context

  • The APOE ε4 allele is the major genetic risk factor for late-onset AD (typically >65 years)
  • Early-onset familial AD is commonly linked to mutations in the APP gene and presenilin (γ-secretase component)
  • Vascular risk factors — diabetes, hypertension, hypercholesterolemia — and prior brain trauma, inactivity, and low cognitive demand increase risk or accelerate progression

Clinical relevance

The hallmark lesions — neuritic plaques rich in Aβ42 and neurofibrillary tangles of hyperphosphorylated tau, accompanied by gliosis and neuronal loss — accumulate in a sequence that mirrors symptom progression. Staging the dominant lesion in a model system is essential for choosing the right pathway readout.

Lateral-brain staging infographic showing the anatomical spread of Alzheimer pathology across four stages: entorhinal cortex and hippocampus (preclinical), cerebral cortex (mild), speech and sensory regions (moderate), and diffuse cortical involvement with global atrophy (severe)
Lateral-brain staging infographic: entorhinal cortex/hippocampus first (preclinical), spreading to cerebral cortex (mild), then speech/reasoning/sensory regions (moderate), then diffuse cortical involvement with global atrophy (severe). Color gradient from light early to deep severe.

Alzheimer's Pathway Genes and Biomarkers You Can Measure

Concrete targets for your ELISA, IHC, Western blot, or qPCR experiments

Selecting the right readout for an Alzheimer's-pathway experiment requires knowing which gene belongs to which functional node. The table below maps key Alzheimer's disease pathway components to their function, standard detection method, and experimental context.

Gene / Protein Pathway Node Function Common Detection Method
APP Amyloid substrate Amyloid precursor protein; substrate for α-/β-/γ-secretase cleavage Western blot, IHC, ELISA
BACE1 β-secretase Initiates amyloidogenic processing; rate-limiting for Aβ generation Western blot, activity assay
PSEN1 (Presenilin-1) γ-secretase Catalytic core of γ-secretase; familial AD mutations shift Aβ42/Aβ40 ratio Western blot, sequencing
Aβ42 (APP-derived peptide) Toxic effector Aggregation-prone amyloid peptide; primary plaque component ELISA (CSF/plasma), IHC
MAPT (Tau) Microtubule / NFT Microtubule-associated protein; hyperphosphorylated form forms PHFs/NFTs Western blot, IHC, ELISA
p-Tau (phospho-tau) NFT marker Hyperphosphorylated tau; correlates with tangle burden and progression ELISA (CSF/plasma), IHC
GSK3B Convergence kinase Central tau kinase; promotes amyloidogenic APP cleavage and apoptosis Western blot, activity assay
CDK5 Tau kinase Proline-directed kinase; tau hyperphosphorylation in AD cortex Western blot, kinase assay
APOE Aβ clearance / risk ApoE4 isoform is the major late-onset AD risk allele; impairs Aβ clearance Genotyping, ELISA, IHC
PP2A (PPP2CA) Tau phosphatase Major tau phosphatase; reduced activity in AD shifts tau to hyperphospho state Western blot, phosphatase assay

When designing an Alzheimer's-pathway experiment, CSF or plasma Aβ42 and phospho-tau are the most validated fluid biomarkers, while tau and p-tau IHC are the standard tissue readouts for tangle burden. For mechanistic work, GSK3β activity assays or BACE1 activity assays provide direct evidence of pathway engagement at the convergence and amyloidogenic-initiation steps respectively.

Frequently Asked Questions

Common questions from researchers working with the Alzheimer's disease pathway.

Q1. What is the Alzheimer's disease pathway and why does it matter for my research?

The Alzheimer's disease pathway is the molecular network that produces the two hallmark lesions of AD: extracellular amyloid plaques from β-/γ-secretase processing of APP, and intraneuronal neurofibrillary tangles of hyperphosphorylated tau. Upstream kinases such as GSK3β and the Wnt axis link impaired Aβ clearance, tau hyperphosphorylation, neuroinflammation, and apoptosis into one self-reinforcing program.

For research it is relevant across neurodegeneration, biomarker discovery, and disease-modifying drug development. Knowing which axis (amyloid vs. tau) and which node is dominant in your model is essential for interpreting results correctly.

Q2. What is the difference between the amyloidogenic and non-amyloidogenic pathways?

Both describe how APP is cleaved. In the non-amyloidogenic pathway, α-secretase cuts APP within the Aβ sequence to release sAPPα and C83; γ-secretase then trims C83 to the harmless P3 fragment — no intact Aβ is produced. This is the preferred physiological route.

In the amyloidogenic pathway, β-secretase (BACE1) cleaves APP to sAPPβ and C99; γ-secretase then liberates full-length Aβ (Aβ40/Aβ42). Aβ42 is the more aggregation-prone, neurotoxic species. A disease-associated shift toward amyloidogenic cleavage plus reduced ApoE/IDE-mediated clearance drives net Aβ accumulation.

Q3. Where can I find the Alzheimer's disease pathway KEGG map?

The Alzheimer's disease KEGG map is catalogued under entry hsa05010 (Homo sapiens), freely accessible at the KEGG PATHWAY database (genome.jp/kegg/pathway.html). It covers APP processing by the secretases, Aβ aggregation, tau hyperphosphorylation, and the downstream calcium, mitochondrial, ER-stress, and apoptotic branches.

A complementary curated resource is "AlzPathway," a comprehensive Alzheimer's signaling map of roughly 1,347 molecules, 1,070 reactions, and 129 phenotypes across neurons, the blood-brain barrier, astrocytes, synapses, and microglia — useful for building targeted gene panels or interpreting pathway-enrichment results.

Q4. What Alzheimer's disease drugs target the pathway and how do they work?

Alzheimer's disease drugs fall into two broad categories:

  • Symptomatic agents: acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine, tacrine) raise synaptic acetylcholine, and the NMDA-receptor antagonist memantine modulates excitotoxicity. They modestly improve cognition but do not alter the underlying biology.
  • Disease-modifying agents: anti-amyloid antibodies (e.g., aducanumab) target the underlying amyloid pathophysiology and represent the first treatments aimed at the pathway itself rather than only symptoms.

Botanical EGb 761 (Ginkgo biloba) is used in Europe for symptomatic relief — neuroprotective and antioxidant — but is not proven to halt progression to dementia.

Q5. What is the best way to confirm Alzheimer's pathway activity in my samples?

The approach depends on which axis you are probing and the mechanistic depth required:

  • Aβ42 ELISA (CSF/plasma/conditioned media): the standard fluid readout of amyloid burden and APP processing balance.
  • Phospho-tau ELISA / IHC: CSF or plasma p-tau and tissue p-tau staining track tangle pathology and correlate with progression.
  • Western blot for APP fragments / BACE1: distinguishes amyloidogenic vs. non-amyloidogenic processing and quantifies the rate-limiting β-secretase.
  • GSK3β activity assay: directly probes the convergence kinase linking amyloid and tau pathology.
  • Targeted gene-expression panel (qPCR): APP, BACE1, PSEN1, MAPT, GSK3B, CDK5, APOE together give the most interpretable picture of pathway state across conditions.

Q6. Does amyloid or tau pathology come first in Alzheimer's disease?

The sequence is still debated, and the evidence supports a coupled rather than strictly linear relationship. The amyloid cascade hypothesis places Aβ accumulation upstream, with Aβ oligomers triggering the kinase activity (GSK3β, CDK5) that hyperphosphorylates tau.

However, intraneuronal hyperphosphorylated tau is detectable in mild dementia even without β-amyloid pathology, and NFT spread correlates more tightly with cognitive decline than plaque load. This suggests tau dysregulation may be an early initiating event in some contexts, with Aβ over-secretion, oxidative stress, and inflammation acting as amplifiers. The practical implication: stage your model and measure both axes rather than assuming a fixed order.